Bayer announced today that its BlueRock Therapeutics subsidiary successfully administered the first dose of its Parkinson’s disease therapies.
Berlin-based Bayer said in a news release that BlueRock successfully administered the dose of its investigational pluripotent stem cell-derived dopaminergic neruons, called DA01, to a Parkinson’s disease patient in an open-label Phase 1 clinical safety and tolerability study.
Additionally, Bayer said its wholly-owned, clinical-stage adeno-associated virus (AAV) gene therapy company, Asklepios BioPharmaceutical (AskBio), is currently recruiting and evaluating patients in an ongoing Phase 1b clinical study to assess the safety and preliminary efficacy of a parallel gene therapy program for Parkinson’s disease.
BlueRock will enroll 10 patients across the U.S. and Canada. Those enrolled will undergo surgical transplantation of the dopamine-producing cells into the putamen deep brain structure, with a…